Literature DB >> 20972624

Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism.

Chaker Ben Salem1, Lynda Ben Salah, Colandane Belajouza, Kamel Bouraoui.   

Abstract

CASE DESCRIPTION: A 40-year-old man with pemphigus foliaceus developed a jaundice and pruritus three weeks after starting azathioprine 100 mg daily. Laboratory investigations revealed a severe cholestatic hepatitis. Azathioprine-induced hepatitis was suspected. The dosage of thiopurine methyltransferase activity showed a low activity of the enzyme and the genotype of this enzyme found a TPMT*3C heterozygous mutant allele. Azathioprine was withdrawn. The icterus regressed progressively and the hepatic tests normalised slowly. The patient had no further episodes of hepatitis over a follow-up period of 6 months.
CONCLUSION: Although, hematotoxicity seems to be associated with homozygous TPMT variants, a possible association between azathioprine hepatotoxicity and a TPMT*3C genotype should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972624     DOI: 10.1007/s11096-010-9443-4

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  10 in total

1.  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.

Authors:  E S Collie-Duguid; S C Pritchard; R H Powrie; J Sludden; D A Collier; T Li; H L McLeod
Journal:  Pharmacogenetics       Date:  1999-02

2.  Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.

Authors:  Samar I Hamdy; Masahiro Hiratsuka; Kaori Narahara; Naomi Endo; Mervat El-Enany; Nadia Moursi; Mohammed S-E Ahmed; Michinao Mizugaki
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

3.  Treatment options for pemphigus foliaceus.

Authors:  S L Fernando; A J Broadfoot
Journal:  G Ital Dermatol Venereol       Date:  2009-08       Impact factor: 2.011

4.  Thiopurine methyltransferase alleles in British and Ghanaian populations.

Authors:  M M Ameyaw; E S Collie-Duguid; R H Powrie; D Ofori-Adjei; H L McLeod
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

5.  Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis.

Authors:  F Mion; B Napoleon; F Berger; M Chevallier; S Bonvoisin; L Descos
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

Review 6.  Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

Authors:  Jenny E Higgs; Katherine Payne; Chris Roberts; William G Newman
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

7.  [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].

Authors:  Michel Biour; Chaker Ben Salem; Olivier Chazouillères; Jean-Didier Grangé; Lawrence Serfaty; Raoul Poupon
Journal:  Gastroenterol Clin Biol       Date:  2004 Aug-Sep

8.  Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.

Authors:  Hua-Wen Xin; Hui Xiong; Xiao-Chun Wu; Qing Li; Lei Xiong; Ai-Rong Yu
Journal:  Eur J Clin Pharmacol       Date:  2008-12-02       Impact factor: 2.953

9.  Treatment of psoriasis with azathioprine.

Authors:  A Du Vivier; D D Munro; J Verbov
Journal:  Br Med J       Date:  1974-01-12

Review 10.  Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity.

Authors:  J Romagnuolo; D C Sadowski; E Lalor; L Jewell; A B Thomson
Journal:  Can J Gastroenterol       Date:  1998-10       Impact factor: 3.522

  10 in total
  5 in total

1.  Severe cholestasis due to azathioprine in Behcet's disease.

Authors:  Kadir Gisi; Murat Ispiroglu; Bulent Kantarceken; Hamide Sayar
Journal:  BMJ Case Rep       Date:  2019-03-31

2.  Azathioprine induced hepatitis in patients with inflammatory bowel disease.

Authors:  Rajaventhan Srirajaskanthan; Dilshad Valliani
Journal:  Int J Clin Pharm       Date:  2011-09-03

Review 3.  Pruritus: management algorithms and experimental therapies.

Authors:  Martin Steinhoff; Ferda Cevikbas; Akihiko Ikoma; Timothy G Berger
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 4.  Azathioprine-induced hepatitis and cholestasis occurring 1 year after treatment.

Authors:  Jason Chertoff; Sabikha Alam; Michael Black; Islam Y Elgendy
Journal:  BMJ Case Rep       Date:  2014-12-03

5.  High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients.

Authors:  Marc Girardin; Antoine Hadengue; Jean-Louis Frossard
Journal:  World J Clin Cases       Date:  2018-04-16       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.